An NK cell line (NK92-41BB) expressing high levels of granzyme is engineered to express the high affinity chimeric genes CD16/CAR

[1]  A. Rosato,et al.  Anti-PSMA CAR-Engineered NK-92 Cells: An Off-the-Shelf Cell Therapy for Prostate Cancer , 2020, Cells.

[2]  J. Schlom,et al.  PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations , 2020, Journal for immunotherapy of cancer.

[3]  M. Minden,et al.  CD16+NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice , 2018, Haematologica.

[4]  Xuejun Zhu,et al.  Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody , 2017, Oncotarget.

[5]  Yangqiu Li,et al.  Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells , 2017, Journal of Hematology & Oncology.

[6]  Christopher G. Adda,et al.  Dynamic interactions between prophages induce lysis in Propionibacterium acnes. , 2017, Research in microbiology.

[7]  J. Schlom,et al.  An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele , 2016, Oncotarget.

[8]  H. Klingemann,et al.  Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells , 2016, Front. Immunol..

[9]  H. Vié,et al.  In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer , 2015, Journal of immunology research.

[10]  A. Björklund,et al.  Therapeutic Potential and Challenges of Natural Killer Cells in Treatment of Solid Tumors , 2015, Front. Immunol..

[11]  D. Teachey,et al.  Toxicity management for patients receiving novel T-cell engaging therapies , 2014, Current opinion in pediatrics.

[12]  K. Campbell,et al.  Natural killer cell biology: an update and future directions. , 2013, The Journal of allergy and clinical immunology.

[13]  Jumei Shi,et al.  Valproic acid upregulates NKG2D ligand expression and enhances susceptibility of human renal carcinoma cells to NK cell-mediated cytotoxicity , 2013, Archives of medical science : AMS.

[14]  Björn Önfelt,et al.  Classification of human natural killer cells based on migration behavior and cytotoxic response. , 2013, Blood.

[15]  H. Reyburn,et al.  Human NKG2D-ligands: cell biology strategies to ensure immune recognition , 2012, Front. Immun..

[16]  M. Cheng,et al.  Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor , 2011, Cancer Gene Therapy.

[17]  U. V. von Andrian,et al.  Adaptive immune responses mediated by natural killer cells , 2010, Immunological reviews.

[18]  K. Fukui,et al.  Development of novel humanized anti‐CD20 antibodies based on affinity constant and epitope , 2010, Cancer science.

[19]  Louis M Weiner,et al.  Monoclonal antibodies for cancer immunotherapy , 2009, The Lancet.

[20]  M. Ychou,et al.  Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  B. Seliger,et al.  Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas , 2008, Proceedings of the National Academy of Sciences.

[22]  W. Yokoyama,et al.  Licensing of natural killer cells by self‐major histocompatibility complex class I , 2006, Immunological reviews.

[23]  T. Blankenstein,et al.  Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors , 2004, European journal of immunology.

[24]  G. Salles,et al.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. , 2002, Blood.

[25]  M. Caligiuri,et al.  Interleukin‐2 enhances the natural killer cell response to Herceptin‐coated Her2 / neu‐positive breast cancer cells , 2001, European journal of immunology.

[26]  Scott,et al.  Changes in biosynthesis and degradation of juvenile hormone during breeding by burying beetles: a reproductive or social role? , 2001, Journal of insect physiology.

[27]  T. Tonn,et al.  Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. , 1999, Human gene therapy.

[28]  M. Nagarkatti,et al.  Role of spontaneous and interleukin-2-induced natural killer cell activity in the cytotoxicity and rejection of Fas+ and Fas- tumor cells. , 1998, Blood.

[29]  R. Reisfeld,et al.  Monoclonal antibodies in cancer immunotherapy. , 1992, Clinics in laboratory medicine.

[30]  M. Nagarkatti,et al.  Role of Spontaneous and Interleukin-2–Induced Natural Killer Cell Activity in the Cytotoxicity and Rejection of Fas+and Fas− Tumor Cells , 1998 .

[31]  D. Roos,et al.  Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. , 1997, Blood.